Novel Effective Therapeutic Regimen for Recurrent/Metastatic Head and Neck Squamous Cell Cancer: Concurrent Triple Oral Metronomic Chemotherapy and Immunotherapy-Reference-Cited by-同舟云学术

Novel Effective Therapeutic Regimen for Recurrent/Metastatic Head and Neck Squamous Cell Cancer: Concurrent Triple Oral Metronomic Chemotherapy and Immunotherapy

Published:2024-08-01 Issue:3 Volume:7 Page:171-177
ISSN:2590-017X
Container-title:Journal of Immunotherapy and Precision Oncology
language:en
Short-container-title:

Author:

Limaye Sewanti¹²,Menon Mohan²,Singh Shambhavi¹^ORCID,Kataria Pritam²,Shreenivas Aditya V.³,Datar Rajan⁴,Patil Darshana⁴,Kumar Prashant⁵,Shah Niyati¹²,Sheth Hardik²,Sneha Suku⁶,Madre Chetan¹²,Deshpande Ruturaj¹²,Menon Narayan K.²,Dandekar Prasad⁷,Haribhakti Vijay⁸

Affiliation:

1. 1 Department of Precision Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India

2. 2 Department of Medical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India

3. 3 Division of Hematology and Medical Oncology, Medical College of Wisconsin Cancer Centre, Milwaukee, Wisconsin, USA

4. 4 Datar Cancer Genetics, Nasik, India

5. 5 Karkinos Foundation, Mumbai, India

6. 6 Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

7. 7 Department of Radiation Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India

8. 8 Department of Surgical Oncology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, India

Publisher

Innovative Healthcare Institute

Link

https://meridian.allenpress.com/innovationsjournals-JIPO/article-pdf/7/3/171/3421073/i2590-017x-7-3-171.pdf

Reference30 articles.

1. Head and neck cancer: a global perspective on epidemiology and prognosis;Sankaranarayanan;Anticancer Res,1998

2. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016

3. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial;Seiwert;Lancet Oncol,2016

4. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study;Cohen;Lancet,2019

5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study;Burtness;Lancet,2019